Podoplanin is a substrate of presenilin-1/γ-secretase

Podoplanin (PDPN) is a mucin-like transmembrane glycoprotein that plays an important role in development and cancer. Here, we provide evidence that the intracellular domain (ICD) of podoplanin is released into the cytosol following a sequential proteolytic processing by a metalloprotease and γ-secretase. Western blotting and cell fractionation studies revealed that HEK293T and MDCK cells transfected with an eGFP-tagged podoplanin construct (PDPNeGFP, 50-63 kDa) constitutively express two C-terminal fragments (CTFs): a ∼33 kDa membrane-bound PCTF33, and a ∼29 kDa cytosolic podoplanin ICD (PICD). While pharmacological inhibition of metalloproteases reduced the expression of PCTF33, treatment of cells with γ-secretase inhibitors resulted in enhanced PCTF33 levels. PCTF33 processing by γ-secretase depends on presenilin-1 (PS1) function: cells expressing a dominant negative form of PS1 (PS1 D385N), and mouse embryonic fibroblasts (MEFs) genetically deficient in PS1, but not in PS2, show higher levels of PCTF33 expression with respect to wild-type MEFs. Furthermore, transfection of PS1 deficient MEFs with wild-type PS1 (PS1 wt) decreased PCTF33 levels. N-terminal amino acid sequencing of the affinity purified PICD revealed that the γ-secretase cleavage site was located between valines 150 and 151, but these residues are not critical for proteolysis. We found that podoplanin CTFs are also generated in cells expressing podoplanin mutants harboring heterologous transmembrane regions. Taken together, these results indicate that podoplanin is a novel substrate for PS1/γ-secretase. © 2013 Elsevier Ltd. All rights reserved.This work was supported by grants SAF2010-19152 from the Spanish Ministry of Economy and Competitiveness and S2010/BMD-2359 (Skin Model-CM) from the Community of Madrid. M.M.Y. and G.d.C. were funded during part of this work by the Formación de Personal Investigador and Juan de la Cierva programs, respectively. EMV is funded by the Spanish Association for Cancer Research Foundation (AECC).Peer Reviewe